Oncology Impact Fund (Cayman) Management L.P., 10% Owner at iTeos Therapeutics, Inc. (ITOS), sold 57,230 shares at $27.53 ($1.6M) on 2021-10-15, disclosed to the SEC on 2021-10-18.
Open-market sale of $1.6M ITOS by 10% Owner. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $27.53 | 14,882 | $410K | 26.1% |
| 2 | $27.53 | 14,882 | $410K | 26.1% |
| 3 | $28.01 | 3,413 | $96K | 6.1% |
| 4 | $28.01 | 3,413 | $96K | 6.1% |
| 5 | $27.14 | 10,320 | $280K | 17.8% |
| 6 | $27.14 | 10,320 |
| $280K |
| 17.8% |
| Total | $27.45 avg | 57,230 | $1.6M | 100% |
| Filing → |
| ITOS | SELL | 2021-11-24 | $8.9M | — | Filing → |
| ITOS | SELL | 2021-10-12 | $4.6M | — | Filing → |
| ITOS | SELL | 2021-09-20 | $8.7M | — | Filing → |